Morningstar Acciones

Smith & Nephew PLC SN. StarRatingValueLabel_5Mr. Lee Davidson, Head of Quantitative Research

Último Precio
984,40
Cambio del día
20,00|2,07%

a 26/04/2024
13:41:13 BST | GBX  Minimum 15 Minutes Delay.

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
984,20 - 984,60965,00 - 986,201.283.6443.600.8998,43Bil
Último Cierre52 Week RangeP/BeneficioDividendo %ISIN
964,40887,00 - 1.316,7539,923,14GB0009223206

Cotización Smith & Nephew

Rentabilidad 25/04/2024

 Chg (%)  
Smith & Nephew PLC-3,58 
FTSE 100 TR GBP2,33
 
Cuentas Financieras
202120222023
More...
Cuenta de Resultados
Turnover5.212,005.215,005.549,00
Operating Profit728,00679,00660,00
Net Profit524,00223,00263,00
Reported EPS0,600,260,30
Balance
Activo Corriente4.424,003.856,004.030,00
Activos no corrientes6.496,006.110,005.957,00
Total Activo 10.920,009.966,009.987,00
Pasivo corriente2.131,001.715,002.271,00
Total Pasivo5.352,004.707,004.770,00
Total Equity5.568,005.259,005.217,00
Flujo de Caja
Flujo de caja operativo974,00515,00733,00
Variación neta de tesorería-459,00-930,00-40,00
Posiciones Directivos
TradedActionNotifierCotizaciónCantidadValor
More...
21/12/2023Transfer inMr. Deepak S. Nath0,0084.8550,00
21/12/2023SaleMr. Deepak S. Nath1.061,2534.479365.908,00
13/11/2023SaleMr. Deepak S. Nath10,011.96119.631,00
13/11/2023Transfer inMr. Deepak S. Nath0,004.7880,00

Perfil de la compañía

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Sector

Atención sanitaria

Industria

Dispositivos Médicos

Índice

FTSE 100, FTSE 350, FTSE All Share, FTSE Eurotop 300, FTSE techMARK Focus, FTSE techMARK All Share

Next Event 01/05/2024

Annual General Meeting
Ratios
Comp
PER (E)43,76
Div Yld (E)2,91
PEG (E)0,53
ROCE5,56
Op Mrgn11,90
EPS Grwth0,08
Dividendos
AntLatest
More...
Record Date06/10/2302/04/24
Ex-Div05/10/2328/03/24
Paid01/11/2322/05/24
Amnt11,8918,41
Directivos
More...
Non-Executive Director, Senior Independent DirectorMr. Marc E. Owen
Non-Executive DirectorMr. Charles Richard Medlock
Non-Executive Director, ChairmanMr. Rupert C Soames OBE
Non-Executive DirectorMr. Jeremy Kim Maiden
Non-Executive DirectorMs. Angie Risley
Non-Executive DirectorMs. Joanna Christine Hallas
Non-Executive DirectorDr. Katarzyna Mazur-Hofsaess
Executive Director, Chief Executive OfficerMr. Deepak S. Nath
Non-Executive DirectorMr. Robert J. White
Non-Executive DirectorDr. John Ma
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.